In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...